These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7358870)

  • 1. Withdrawal syndrome after guanabenz.
    Walker BR; Geczy M
    J Clin Pharmacol; 1980 Jan; 20(1):69-70. PubMed ID: 7358870
    [No Abstract]   [Full Text] [Related]  

  • 2. Withdrawal syndrome following cessation of guanabenz therapy.
    Ram CV; Holland OB; Fairchild C; Gomez-Sanchez CE
    J Clin Pharmacol; 1979; 19(2-3):148-50. PubMed ID: 422739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of guanabenz withdrawal on blood pressure and plasma catecholamines.
    Buckalew VM; Burgess R; Strandhoy JW
    J Cardiovasc Pharmacol; 1984; 6 Suppl 5():S830-2. PubMed ID: 6084134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sinoatrial and atrioventricular dysfunction associated with the use of guanabenz acetate.
    LaRusso P; Jessup SA; Rogers FJ; Rogers JC
    Can J Cardiol; 1988 Apr; 4(3):146-8. PubMed ID: 3378199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrinologic effects of antihypertensive therapy with guanabenz or hydrochlorothiazide.
    Eldridge JC; Strandhoy J; Buckalew VM
    J Cardiovasc Pharmacol; 1984; 6 Suppl 5():S776-80. PubMed ID: 6084124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cimetidine withdrawal.
    Hoskyns BL
    Lancet; 1977 Jan; 1(8005):254-5. PubMed ID: 64780
    [No Abstract]   [Full Text] [Related]  

  • 7. Guanabenz acetate: a new, long-acting alpha-two adrenergic agonist for opioid withdrawal.
    Tennant FS; Rawson RA
    NIDA Res Monogr; 1984 Mar; 49():338-43. PubMed ID: 6090917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanabenz (Wytensin) a new antihypertensive drug.
    Med Lett Drugs Ther; 1983 Jan; 25(627):11-2. PubMed ID: 6336818
    [No Abstract]   [Full Text] [Related]  

  • 9. [Studies on the physical dependence liability to guanabenz].
    Kaneto H; Kosaka N; Takasu M; Mino T
    Nihon Yakurigaku Zasshi; 1982 Nov; 80(5):405-15. PubMed ID: 6891939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.
    Holmes B; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Sep; 26(3):212-29. PubMed ID: 6352237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanabenz in essential hypertension.
    McMahon FG; Ryan JR; Jain AK; Vargas R; Vanov SK
    Clin Pharmacol Ther; 1977 Mar; 21(3):272-7. PubMed ID: 319938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary clinical trial with a new hypotensive, guanabenz, in a group of hypertensive patients.
    De Ridder JH; Marchandise P
    Acta Cardiol; 1980; 35(5):349-55. PubMed ID: 6970485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of guanabenz and hydrochlorothiazide on blood pressure and plasma renin activity.
    Holland OB; Fairchild C; Gomez-Sanchez CE
    J Clin Pharmacol; 1981 Apr; 21(4):133-9. PubMed ID: 7016928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of guanabenz versus clonidine.
    Leary WP; Asmal AC; Williams PC
    S Afr Med J; 1979 Jan; 55(3):83-5. PubMed ID: 371036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antihypertensive effects of guanabenz and methyldopa.
    Walker BR; Deitch MW; Schneider BE; Hare LE
    Clin Ther; 1981; 4(4):275-84. PubMed ID: 7332915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guanabenz for adolescent hypertension.
    Walson PD; Rath A; Kilbourne K; Deitch MW
    Pediatr Pharmacol (New York); 1984; 4(1):1-6. PubMed ID: 6739181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of guanabenz in adolescent hypertension.
    Walson PD; Graves P; Rath A; Kilbourne K; Deitch MW
    J Cardiovasc Pharmacol; 1984; 6 Suppl 5():S814-7. PubMed ID: 6084131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of guanabenz, alpha 2 central agonist, on the activity of the sympathetic nervous system during dynamic and isometric physical exercise].
    Fariello R; Agabiti-Rosei E; Alicandri C; Romanelli G; Muiesan G; Renzetti I
    Minerva Cardioangiol; 1984 May; 32(5):273-9. PubMed ID: 6382054
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose-response relationship of single oral doses of guanabenz in hypertensive patients.
    Weidler DJ; Garg DC; Jallad NS
    J Cardiovasc Pharmacol; 1984; 6 Suppl 5():S762-5. PubMed ID: 6084121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of guanabenz in patients with impaired liver function.
    Lasseter KC; Shapse D; Pascucci VL; Chiang ST
    J Cardiovasc Pharmacol; 1984; 6 Suppl 5():S766-70. PubMed ID: 6084122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.